Boston Firm Raises Funds for Alzheimer's Drug Trial
Acta Pharmaceuticals secures $24 million to advance a new oral treatment candidate into early-stage clinical testing.
Updated on Oct. 15, 2026 in Alzheimer’s
Live Poll
Should pharmaceutical research prioritize early disease prevention over the treatment of existing symptoms?
Boston-based Acta Pharmaceuticals has successfully raised $24 million in seed financing to support its lead drug candidate, GSM-779690T. The company is now initiating a Phase 1 clinical trial to evaluate the once-daily oral therapy for Alzheimer's disease.
Why it matters
This financing marks a critical step for the firm as it moves its gamma-secretase modulator program from extensive preclinical research into human testing. The drug aims to address the disease through early intervention by modifying specific protein levels associated with Alzheimer's pathology.
The clinical trial (NCT07690228) utilizes a randomized, double-blind, placebo-controlled design to test the drug candidate. This follows $70 million in prior preclinical development funding for the GSM program.
The players
Acta Pharmaceuticals
A Boston-based biotechnology company founded in 2022 to develop early intervention therapies for Alzheimer's disease.
Massachusetts General Hospital
A leading research hospital that provided foundational intellectual property regarding drug combinations for the company.
The details
GSM-779690T is designed to reduce Aβ42 protein levels while simultaneously increasing levels of Aβ37 and Aβ38 to mitigate Alzheimer's pathology. The therapy was developed using research licensed from Massachusetts General Hospital and University of California, San Diego, employing mini-organoid Alzheimer's-in-a-Dish models.
Timeline
Acta Pharmaceuticals was established in 2022.
The company plans to evaluate the drug candidate in a Phase 1 clinical trial during October 2026.
The Big Picture
The initiative represents a direct evolution of the Alzheimer's-in-a-Dish laboratory models into clinical application. This transition moves the research paradigm from organoid-based screening toward verifying these therapeutic combinations in human subjects.
This development introduces a new oral therapy option into the clinical pipeline, potentially simplifying future treatment routines with its once-daily design. Patients and families will need to monitor the trial progress to determine future eligibility and potential clinical outcomes.
The takeaway
The progression of this gamma-secretase modulator highlights the ongoing shift toward precision protein targeting in neurodegenerative therapy. Researchers continue to leverage advanced laboratory organoids to identify and validate effective drug combinations before moving to human trials.
What happens next
The company is scheduled to conduct its Phase 1 clinical trial for GSM-779690T throughout October 2026.
Further reading
Learn more about the latest research and treatment developments in our Alzheimer’s section.
More information
View the full clinical trial study details on the official government registry.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should pharmaceutical research prioritize early disease prevention over the treatment of existing symptoms?
